Mesothelin-targeted bispecific antibodies drive synthetic agonistic receptor - Transduced T cells to mediate specific and conditional therapy of human pancreatic cancer models

Benmebarek M.; Karches C.; Schmidbauer M.; Kurzay M.; Klaus R.; Geiger M.; Rataj F.; Cadilha B.; Keyl J.; Lesch S.; Heise C.; Murr R.; vom Berg J.; Jastroch M.; Lamp D.; Niederfellner G.; Sustmann C.; Endres S.; Klein C.; Kobold S.

首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >Mesothelin-targeted bispecific antibodies drive synthetic agonistic receptor - Transduced T cells to mediate specific and conditional therapy of human pancreatic cancer models

【24h】

Mesothelin-targeted bispecific antibodies drive synthetic agonistic receptor - Transduced T cells to mediate specific and conditional therapy of human pancreatic cancer models

机译：中学素靶向双特异性抗体驱动合成激动受体 - 转导的T细胞，介导人胰腺癌模型的特定和条件治疗

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2018年第2018期|共1页
作者
Benmebarek M.; Karches C.; Schmidbauer M.; Kurzay M.; Klaus R.; Geiger M.; Rataj F.; Cadilha B.; Keyl J.; Lesch S.; Heise C.; Murr R.; vom Berg J.; Jastroch M.; Lamp D.; Niederfellner G.; Sustmann C.; Endres S.; Klein C.; Kobold S.;
展开▼
作者单位

LMU Div Clin Pharmacolog Munich Germany;

LMU Div Clin Pharmacolog Munich Germany;

LMU Div Clin Pharmacolog Munich Germany;

LMU Div Clin Pharmacolog Munich Germany;

LMU Div Clin Pharmacolog Munich Germany;

Roche Innovat Ctr Zurich Schlieren Switzerland;

LMU Div Clin Pharmacolog Munich Germany;

LMU Div Clin Pharmacolog Munich Germany;

LMU Div Clin Pharmacolog Munich Germany;

LMU Div Clin Pharmacolog Munich Germany;

LMU Div Clin Pharmacolog Munich Germany;

Roche Innovat Ctr Zurich Schlieren Switzerland;

Univ Zurich Inst Lab Anim Sci Zurich Switzerland;

Helmholtz Zentrum Munchen Helmholtz Diabet Ctr Munich Germany;

Helmholtz Zentrum Munchen Helmholtz Diabet Ctr Munich Germany;

Roche Innovat Ctr Penzberg Germany;

Roche Innovat Ctr Penzberg Germany;

LMU Div Clin Pharmacolog Munich Germany;

Roche Innovat Ctr Zurich Schlieren Switzerland;

LMU Div Clin Pharmacolog Munich Germany;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Mesothelin-targeted bispecific antibodies drive synthetic agonistic receptor - Transduced T cells to mediate specific and conditional therapy of human pancreatic cancer models [J] . Benmebarek M., Karches C., Schmidbauer M., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2018,第期

机译：中学素靶向双特异性抗体驱动合成激动受体 - 转导的T细胞，介导人胰腺癌模型的特定和条件治疗
2. Characterization of bispecific antibodies that drive synthetic agonistic receptor - transduced T cells to mediate specific and conditional therapy in human pancreatic cancer models [J] . Benmebarek M., Karches C. H., Schmidbauer M. L., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2019,第期

机译：促进合成激动受体 - 转导T细胞的双特异性抗体的表征在人胰腺癌模型中介导特异性和条件治疗
3. P06.01?Bispecific antibody-driven synthetic agonistic receptor – transduced T cells mediate specific and conditional therapy in melanoma cancer models [J] . M Benmebarek, J Keyl, F M?rkl, Journal for ImmunoTherapy of Cancer . 2020,第Suppla2期

机译：p06.01？双特异性抗体驱动的合成激动受体 - 转导T细胞在黑素瘤癌模型中介导特异性和有条件治疗
4. Preliminary study of cytotoxic effects of photodynamic therapy and immunotherapy on human pancreatic cancer cells [C] . Luowei Wang, Bolin Liu, Yang K. Chen, Biophotonics and immune responses IV . 2009

机译：光动力疗法和免疫疗法对人胰腺癌细胞的细胞毒性作用的初步研究
5. A novel approach to control and regulate the classical complement pathway: Highly specific inhibition of C1q globular head binding to human IgG using an engineered single chain antibody variable fragment; recruiting C1q to HER2 /neu positive cells using truncated bispecific antibodies [D] . Hwang, Hee Young 2007

机译：一种控制和调节经典补体途径的新方法：使用工程化的单链抗体可变片段高度特异性地抑制C1q球头与人IgG的结合；使用截短的双特异性抗体将C1q募集到HER2 / neu阳性细胞
6. A Combination of DR5 Agonistic Monoclonal Antibody with Gemcitabine Targets Pancreatic Cancer Stem Cells and Results in Long-term Disease Control in Human Pancreatic Cancer Model [O] . N.V. Rajeshkumar, Zeshaan A. Rasheed, Elena García-García, -1

机译：DR5激动单克隆抗体与吉西他滨一种基于组合瞄准胰腺癌干细胞和结果长期疾病控制在人胰腺癌模型
7. Characterization of bispecific antibodies that drive synthetic agonistic receptor - transduced T cells to mediate specific and conditional therapy in human pancreatic cancer models [O] . M. Benmebarek, C.H. Karches, M.L. Schmidbauer, 2019

机译：促进合成激动受体 - 转导T细胞的双特异性抗体的表征在人胰腺癌模型中介导特异性和条件治疗

Mesothelin-targeted bispecific antibodies drive synthetic agonistic receptor - Transduced T cells to mediate specific and conditional therapy of human pancreatic cancer models

著录项

相似文献

相关主题

期刊订阅